November 2008
Worldwide Biotech;Nov2008, Vol. 20 Issue 11, p2
Trade Publication
The article reports that Chinese vaccines developer Sinovac Biotech Ltd. has initiated the development of a vaccine human enterovirus 71 (EV 71), which causes hand, foot, and mouth disease (HFMD). Sinovac will be supplied with epidemiology study results from the outbreak area to facilitate its vaccine research and development initiatives. Sinovac president and chief executive officer (CEO) Weidong Yin anticipates that the vaccine has the potential to become another flagship product.


Related Articles

  • Sinovac Jumps on Results for Hand, Foot and Mouth Vaccine. Shaffer, Catherine // BioWorld Today;3/15/2013, Vol. 24 Issue 50, p1 

    The article discusses the results of the Phase III data of the double-blind, randomized, placebo-controlled trial of Sinovac Biotech Ltd.'s enterovirus 7I (EV 7I) vaccine which reveal efficacy, immunogenicity and safety against hand, foot and mouth disease (HFMD). The data showed a 95.4 percent...

  • China Human Vaccine Industry Report 2011-2012.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article informs that a report titled "China Human Vaccine Industry Report 2011-2012" has been added to the Research and Markets offering. It mentions the companies which have been profiled in the report which include Sinovac Biotech Ltd, Liaoning Chengda Co. Ltd and China National Biotec...

  • VACCINE REPORT.  // BioPharm International;May2008, Vol. 21 Issue 5, p12 

    The article offers news briefs related to vaccines. Sinovac Biotech Ltd. has announced that Panflu, its pandemic influenza H5N1 whole viron inactivated vaccine, has been granted a production license by the China State Food and Drug Administration. The U.S. Food and Drug Administration announced...

  • Sinovac gets GMP Certificate for Flu/Hepatitis A.  // Worldwide Biotech;Sep2011, Vol. 23 Issue 9, p8 

    The article reports that China-based biopharmaceutical maker Sinovac Biotech Ltd. has received a good manufacturing practice (GMP) certification from the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) of Mexico Ministry of Health for its flu/hepatitis A vaccine. The...

  • SINOVAC UNVEILS PRELIMINARY UNADITED 3RD QTR 2010 SALES.  // Biotech Financial Reports;Nov2010, Vol. 17 Issue 11, p6 

    The article reports on the preliminary unaudited sales of the China-based biopharmaceutical company Sinovac Biotech Ltd. in the third quarter of 2010. It notes that the company has expected its third quarter 2010 sales to be in the range of approximately 9 to 10 million U.S. dollars and its...

  • Vaccine Maker Sinovac Rises After Robust 2Q Earnings Report. Ellis, Shannon // BioWorld Today;8/26/2013, Vol. 24 Issue 163, p1 

    The article reports financial performance recorded by vaccine manufacturer Sinovac Biotech Ltd. for the second quarter of 2013. It details the increase in total sales, gross profits and share value in the said period. In addition to its export activities to various countries including Mongolia...

  • Sinovac: Panflu on track in pandemic flu.  // PharmaWatch: Monthly Review;May2006, Vol. 5 Issue 5, p38 

    The article reports on the completion of Sinovac Biotech Ltd.'s phase I clinical trial of its avian influenza vaccine Panflu on the shot regimen of either the vaccine or placebo. The action represents another step on the product candidate's way to becoming a much-needed addition to global...

  • Sinovac wins purchase order from Shanghai government for hepatitis A vaccine.  // PharmaWatch: Biotechnology;Jan2010, Vol. 9 Issue 1, p27 

    The article reports on the selection of Shanghai government on vaccine manufacturer Sinovac Biotech Co. Ltd. to supply Healive inactivated hepatitis A vaccine in China. It notes that the Chinese authority rewarded Sinovac with three million dollars. According to Sinovac Biotech chairman Weidong...

  • SINOVAC BIOTECH SUBMITS CLINICAL TRIAL APPLICATION FOR PCV.  // Worldwide Biotech;Apr2011, Vol. 23 Issue 4, p4 

    The article reports the clinical trial application of biopharmaceutical firm Sinovac Biotech Ltd. for its 13-valent pneumococcal conjugate vaccine (PCV) to the State Food and Drug Administration (SFDA) of China. The vaccine regulatory system of the SFDA passed the evaluation of the World Health...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics